University of Warsaw

About: University of Warsaw is a education organization based out in Warsaw, Poland. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 20832 authors who have published 56617 publications receiving 1185084 citations. The organization is also known as: Uniwersytet Warszawski & Warsaw University.

Indications of suppression of excited? States in Pb-Pb collisions at sNN2.76 TeV

Abstract: A comparison of the relative yields of Upsilon resonances in the mu(+) mu(-) decay channel in PbPb and pp collisions at a centre-of-mass energy per nucleon pair of 2.76 TeV, is performed with data collected with the CMS detector at the LHC. Using muons of transverse momentum above 4 GeV/c and pseudorapidity below 2.4, the double ratio of the Upsilon(2S) and Upsilon(3S) excited states to the Upsilon(1S) ground state in PbPb and pp collisions,(Upsilon(2S+3S)/Upsilon(1S)[PbPb])/(Upsilon(2S+3S)/Upsilon(1S)[pp]), is found to be 0.31 - 0.15 + 0.19 (stat.) +/- 0.03 (syst.). The probability to obtain the measured value, or lower, if the true double ratio is unity, has been calculated to be less than 1%.

Myeloid Cell-Derived Arginase in Cancer Immune Response

Abstract: Amino acid metabolism is a critical regulator of the immune response, and its modulating becomes a promising approach in various forms of immunotherapy. Insufficient concentrations of essential amino acids restrict T-cells activation and proliferation. However, only arginases, that degrade L-arginine, as well as enzymes that hydrolyze L-tryptophan are substantially increased in cancer. Two arginase isoforms, ARG1 and ARG2, have been found to be present in tumors and their increased activity usually correlates with more advanced disease and worse clinical prognosis. Nearly all types of myeloid cells were reported to produce arginases and the increased numbers of various populations of myeloid-derived suppressor cells and macrophages correlate with inferior clinical outcomes of cancer patients. Here, we describe the role of arginases produced by myeloid cells in regulating various populations of immune cells, discuss molecular mechanisms of immunoregulatory processes involving L-arginine metabolism and outline therapeutic approaches to mitigate the negative effects of arginases on antitumor immune response. Development of potent arginase inhibitors, with improved pharmacokinetic properties, may lead to the elaboration of novel therapeutic strategies based on targeting immunoregulatory pathways controlled by L-arginine degradation.